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Abstract: Tyrosine kinase inhibitor (TKI) therapy is the standard 
treatment for chronic phase (CP)-chronic myeloid leukemia (CML), yet 
patients in blast crisis (BC) phase of CML are unlikely to respond to TKI 
therapy. The transcription factor E2F1 is a down-stream target of the 
tyrosine kinase BCR-ABL1 and is up-regulated in TKI-resistant leukemia 
stem cells (LSC). Pyrrole imidazole polyamides (PA) are minor groove 
binders which can be programmed to target DNA sequences in a gene-
selective manner. This manuscript describes such an approach with a PA 
designed to down-regulate E2F1 controlled gene expression by targeting a 
DNA sequence within 100 base pairs (bp) upstream of the E2F1 consensus 
sequence. Human BC-CML KCL22 cells were assessed after treatment with PA, 
TKI or their combination. Our PA inhibited BC-CML cell expansion based on 
cell density analysis compared to an untreated control after a 48-hour 
time-course of PA treatment. However, no evidence of cell cycle arrest 
was observed among BC-CML cells treated with PA, with respect to their no 
drug control counterparts. Thus, this work demonstrates that PAs are 
effective in inhibiting E2F1 TF activity which results in a temporal 
reduction in BC-CML cell number. We envisage that PAs could be used in 
the future to map genes under E2F1 control in CML LSCs. 
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*Graphical Abstract
Scientific Communication 
An investigation of targeted inhibition of transcription factor activity with pyrrole 
imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells 
 
Abstract: 
Tyrosine kinase inhibitor (TKI) therapy is the standard treatment for chronic phase (CP)-chronic 
myeloid leukemia (CML), yet patients in blast crisis (BC) phase of CML are unlikely to respond 
to TKI therapy. The transcription factor E2F1 is a down-stream target of the tyrosine kinase 
BCR-ABL1 and is up-regulated in TKI-resistant leukemia stem cells (LSC). Pyrrole imidazole 
polyamides (PA) are minor groove binders which can be programmed to target DNA sequences 
in a gene-selective manner. This manuscript describes such an approach with a PA designed to 
down-regulate E2F1 controlled gene expression by targeting a DNA sequence within 100 base 
pairs (bp) upstream of the E2F1 consensus sequence. Human BC-CML KCL22 cells were 
assessed after treatment with PA, TKI or their combination. Our PA inhibited BC-CML cell 
expansion based on cell density analysis compared to an untreated control after a 48-hour time-
course of PA treatment. However, no evidence of cell cycle arrest was observed among BC-
CML cells treated with PA, with respect to their no drug control counterparts. Thus, this work 
demonstrates that PAs are effective in inhibiting E2F1 TF activity which results in a temporal 
reduction in BC-CML cell number. We envisage that PAs could be used in the future to map 
genes under E2F1 control in CML LSCs. 
Keywords: Chronic Myeloid Leukemia, Blast Crisis CML, Pyrrole-imidazole Polyamide, E2F 
Transcription Factor 1, Leukemia Stem Cells, Tyrosine Kinase Inhibitor. 
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Background: Knowledge is accumulating on how best to modulate transcription factor (TF) 
activity, an emerging area for development of new therapeutics [1]. Classical small molecule 
inhibitors, which disrupt protein activity through binding to small hydrophobic clefts, can suffer 
from off-target effects, whereas peptidomimetics have low bioavailability [1]. Pyrrole-imidazole 
polyamides (PAs) offer an alternative approach to these strategies by binding to DNA sequences 
and down-regulating expression of target genes [2].  PAs can be programmed to bind to target 
sequences according to established pairing rules [2-4] enabling PAs to inhibit transcriptional 
elongation of RNA polymerase II and TF-DNA binding [2-5].  
 
E2F1 is a well-known TF, which controls cell cycle progression and regulates tumor suppressor 
proteins. E2F1 is upregulated in chronic myeloid leukemia (CML) leukemia stem cells (LSC) 
downstream of the BCR-ABL1 signaling pathway [6]. There is an unmet clinical need to gain a 
greater understanding of the molecular determinants of CML patients developing resistance to 
tyrosine kinase inhibitor (TKI) therapy in the blast crisis (BC) phase [7]. In this study we 
investigated the ability of a PA to disrupt E2F1 function in BC-CML, having previously shown 
activity in chronic phase (CP)-CML cells [8].  
 
Methods: Our approach was to use our designed PA (Fig. 1A), targeting WGWGGW (where W 
= T/A) (Fig. 1B) sequences found 100 base pairs (bp) upstream of the consensus E2F1 binding 
site (TTTCGC) in the promoter region of a suite of E2F1 target genes in BC-CML cells [8]. In 
this way, our PA is able to halt RNA polymerase addition to the transcription machinery, through 
interfering with its binding elements at the promoter of each target gene [9]. 
 
PA was prepared by automated solid phase synthesis using a CS336X synthesizer as previously 
described [10,11].  The synthesizer was programmed in the standard hardware configuration for 
DIC/HOBt (or HBTU/DIEA) protocols. Reagent position 1 was DMF, reagent position 2 was 
dry DMF, reagent position 3 was piperidine/DMF (20%), reagent position 4 was DCM, reagent 
position 5 was TFA/phenol/H2O (92.5:5:2.5), reagent position 6 was DIEA/dry DMF (10%), 
reagent position 7 was 2,4,6-collidine/dry THF (15%), and reagent position 8 was dry THF. 
 
As phosgene and CO2 gas were evolved, the peptide synthesizer was placed in a fume hood and 
the waste gas was treated with aqueous 20% NaOH solution to destroy the excess phosgene. The 
synthesis was carried out on a 0.06 mmol scale (400 mg of the resin; 0.15 mmol/g). Each cycle 
of amino acid addition involved deprotection, amino acid activation and coupling. Two 
successive coupling cycles are employed when coupling pyrrole amino acids to imidazole 
amines; all other couplings are performed with single coupling cycles. 
 
When the coupling of all heterocycles was complete, resin was washed twice with DCM (5 mL, 
calibrated delivery from reagent bottle 4) and deprotected twice (for 2 min and 20 min, 
respectively) with the mixture of TFA/phenol/H2O (5 mL, calibrated delivery from reagent bottle 
5). The RV was drained and the resin was treated with two DCM washes (5 mL from reagent 
bottle 4), a DMF wash (5 mL from reagent bottle 1), a DIEA/dry DMF wash (5 mL from reagent 
bottle 6, bypassing the AA reservoir), a dry THF wash (to wash the needle, 5 mL from reagent 
bottle 8, bypassing the AA reservoir), a DMF wash (5 mL from reagent bottle 1), and a dry DMF 
wash (5 mL from reagent bottle 2). The resin containing the fully-formed PA was treated with 
Cu(OAc)2 in dimethylaminopropylamine (Dp, 20 PL), the suspension was shaken at 55°C for 
16h. After cooling to room temperature, the crude PA was collected by centrifugation and the 
blue solution was diluted with 10% MeCN/H2O/0.1% TFA and purified by semi-preparative RP-
HPLC (Fig. 1C). 
 
Cell viability and density of human KCL22 cells (DSMZ-German Collection of Microorganisms 
and Cell Cultures, DSMZ # ACC 519) when exposed to our PA, TKI (nilotinib), and their 
combination were investigated by trypan blue dye exclusion counting in standard Neubauer 
haemocytometer chambers. The KCL22 cells were seeded at 1 x 105 cells/mL in serum 
supplemented RPMI640. The PA was tested in the micromolar concentration range; nilotinib 
was used at 10 nM which is around its IC50 in our hands for this cell line. For synergy, 
Combination Indices (CI) were calculated manually using the Bliss Independence model 
according to CI = ((EA + EB) – EA.EB) / EAB; where EA is the effect of drug A alone, EB is the 
effect of drug B along and EAB is the effect of the combination.  CI < 1 is synergistic; CI = 1 is 
additive; CI > 1 is antagonistic. 
 
Cell cycle investigation was done using propidium iodide (PI) staining. Briefly, after fixation in 
70% ice-cold ethanol, cells were washed twice in PBS and stained with 2 μL of 100 μg/mL 
RNase (to ensure only the DNA is stained) in 200 μL of 50 μg/mL PI. Samples were analysed by 
flow cytometry in the PE/PerCP channel; data analysis was done using FlowJo software 
(TreeStar). RNA extractions were done using the RNeasy plus micro or mini kits (QIAGEN). 
cDNA samples were made using applied Biosystems High-Capacity RNA-to-cDNA™ Kit 
(ThermoFisher). Gene expression analysis was done using EvaGreen® on the BioMark HD 
System, using flex six IFC (Fluidigm) based on manufacturer’s protocols. Housekeeping gene 
(GAPDH and RNF20) cycle threshold (Ct) values were used to normalise the data of genes of 
interest, generating ΔCt values. ΔCt values of drug treated samples were subtracted from ΔCt of 
the relevant no drug control, generating ΔΔCt values to calculate relative levels of gene 
expression (fold change, 2-ΔΔCt). 
 
Results & Discussion: Our polyamide follows established pairing rules for aromatic pyrrole 
(Py) and imidazole (Im) amino acids whereby Py/Py recognises A·T/T·A, while Im/Py targets 
G·C pairings and Py/Im the reverse (C·G).[10] For more in-depth structural information 
concerning how hairpin polyamides bind to a target sequence, please refer to [12,13]. It may be 
presumed that a PA, with a short half-life, binds and inhibits TF activity within 24 hours in 
culture whereas the biological consequences of altered transcription may lag behind.  Hence, we 
looked at gene expression at 24h, and observed cellular process effects by 48 hours. As can be 
seen in Fig. 2A, the presence of our PA in the culture held back KCL22 cell expansion compared 
to no drug control. Combining a PA with nilotinib seemed to show a greater effect than nilotinib 
alone at 48 hours on cell counts, however the CI was not synergistic. In addition, PI staining was 
used to investigate the cell cycle status. No difference between PA-treated cells and no drug 
control at the same time point was found (Fig. 2B). This suggested that our PA had not caused 
cell cycle arrest. BC-CML cells acquire more genetic lesions with disease progression so are no 
longer unilaterally dependent on BCR-ABL1 like CP-CML cells, so they might show more 
insensitivity to PA, as can develop to TKIs. Contrary to our hypothesis, the complex network of 
cell survival signaling in BC-CML cells due to the additional genetic alterations eluded to earlier 
may help BC-CML cells overcome cell cycle arrest induced consequent to the PA inhibiting 
E2F1 activity. Reduction in cell numbers without apparent cell cycle arrest suggests inhibition of 
E2F1 TF activity by PA in BC-CML cells had induced cell death. 
 
Our PA targets sequences within 100 bp upstream of the 5′ end of the consensus E2F1 binding 
site in the promoter region of E2F1 target genes meaning 42 candidates of 4,300 putative E2F1 
target genes were chosen. 17 of these 42 genes with highest expression in CD34+ hematopoietic 
stem/progenitor cells (based on the Gerber et al., publicly available dataset provided by the 
Stemformatics website [14]), were selected as biomarkers of PA activity by gene expression 
analysis. After complementary DNA (cDNA) primer efficiency testing, 9 genes were selected for 
further study: MRRF, MCM2, SF3B4, GNA13, PSMB8, PET112L, TRIM45, ZNF354B, and 
RARS2. The gene expression results suggested that the PA disrupts E2F1 function by down-
regulating the expression of 7 of the 9 selected E2F1 regulated genes (Fig. 3). Thus, this PA 
could have the potential for development as a chemical probe to inhibit E2F1’s transcriptional 
role of its target genes among BC-CML cells. Interestingly, two genes, namely TRIM45 and 
RARS2 were upregulated in KCL22 PA treated cells in opposition to our hypothesis of down-
regulation. While E2F1 TF activities were targeted by our PA with 7 of 9 E2F1 target genes 
being down-regulated, some KCL22 cells persisted without the apparent need for those gene 
products for their overall survival, so here we might have enriched for viable, resistant KCL22 
cells.  
 
Our PA was efficacious as a single agent at 3 μM concentration limiting KCL22 cell number in 
culture. However, when combined with TKI, despite apparent cooperativity in restricting cell 
numbers, there was statistically no greater effect than either agent alone (synergy) after 48 hours 
in culture, possibly owing to the fact that E2F1 expression itself is controlled by BCR-ABL1. 
Hence, inhibition of the E2F1 would give no added benefit in the context of simultaneous 
targeting of BCR-ABL1 tyrosine kinase activity with TKI. Going forward, we would investigate 
the effect of scheduling drug administration to explore how altering E2F1-controlled gene 
expression by a PA would best contribute to pharmacological ‘synthetic lethality’ improving 
outcomes with TKI alone.  
 
Conclusion: In summary, we have demonstrated that our PA down-regulates the expression of 
E2F1-controlled genes, which causes a restriction in the growth of KCL22 BC-CML cells. 
Taking both our in vitro studies together (in CP-CML and BC-CML), and should in vivo effects 
be demonstrated, we would envisage that our PA approach could be further developed as an 
adjuvant therapy for CP-CML more than BC-CML, or, as a general chemical biological probe of 
E2F1-controlled expression to further investigate TFs such as E2F1 as novel drug targets in 
cancer. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure and analysis of synthesized pyrrole imidazole polyamide.  
A: Structure of the pyrrole imidazole polyamide (PA) designed against E2F1 TF activity in this 
study. B: Schematic preview of our PA binding to the WGWGGW sequence in the minor groove 
of the target DNA, where W = T/A. C: Representative Reverse Phase (RP)-HPLC chromatogram 
of synthesized PA. HRMS (ESI, +ve mode): 1167.5449 [M+H]+.  
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Figure 2. KCL22 cell proliferation and cell cycle status after being treated with PA. 
A: Cell density, as investigated by trypan blue staining, of KCL22 cells during 48h time-course 
after being treated with PA, nilotinib or a combination of both. PA alone reduced proliferation of 
KCL22 cells. The PA effect alone at 48h was not as pronounced as nilotinib alone or in 
combination with nilotinib yet CI for the combination was >1 at 48h. B: Flow cytometry 
histograms of PI staining for cell cycle of KCL22 cells treated with 3 μM PA or no drug control 
at 72 h. There is almost the same proportion of cells at the different cell cycle stages (G1, S, G2, 
M) among those treated with 3 μM PA or no drug control. This is suggestive of PA not having 
any cell cycle arrest effect. Hence the difference in cell counts seen between untreated and 
treated cells in (A) is unlikely to be explained by cell cycle arrest and consequent restriction of 
proliferation. 
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Figure 3. RT-qPCR gene expression results for KCL22 cells treated with 3 μM PA for 24 
hours. Gene expression was determined using Fluidigm platform with EvaGreen® dye at 24 
hours after addition of PA (3 μM) to the cultures. Cycle threshold (Ct) values were normalised by 
two housekeeping genes i.e., GAPDH and RNF20. Gene expression levels are presented as fold-
change (2-ΔΔCt) in the sample versus untreated control. This is suggestive that 7 out of 9 target 
genes are down-regulated after 24 hours of PA treatment. Mean ± SD of three technical 
replicates are shown. 
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